Background:Reccurence or metastasis occurred about 15 percent in patients with early breast cancer(EBC)after operation at 10 years,though the outcomes of patients with EBC were batter than that of other stage's.It is illustrated limitations in conventional prognosis factors such as tumor size,axillary node status,grade and ER,HER2,et al.Genes correlated with breast cancer were identified with the developing of molecules.The synergistic action of these genes is the focus currently.Objective:To study the feasibility of classifying the patients with EBC as good or poor prognosis at molecule level according the expressions of genes correlated with recurrence(HER2,ER,PR,BCL2,Ki-67,BMYB,Cyclin B1,STK15,MMP11,BAG1,NM23,PTEN,P53,P27,VEGF,PCNA).Methods:16 genes correlated with recurrence were selected according literatures.A total of 76 patients with EBC were followed up in this study. The expressions of these genes in 76 patients with EBC were detected by Immunohistochemical two-step method and statistical analysis used by COX proportional hazards model.Results:There are 11 genes correlated with prognosis in univariate analysis with COX proportional hazard model:BCL2,ER,NM23,BAG1,P27,Ki-67, STK15,CyclinB1,HER2,VEGF,MMP11.Among these genes,BCL2,ER, NM23,BAG1 and P27 were negatively correclated with prognosis;on the othe hand,Ki-67,STK15,Cyclin B1,HER2,VEGF and MMP11 were positively correclated with prognosis.In multivariate analysis,there are three genes including BCL2,VEGF and STK15 correlated with prognosis of the patients with EBC.A formula of PI was set up according the three genes.The predictive outcomes with PI were compared with the actual follow-up outcomes.As a result,the sensibility,specificity and coincidence were 76.19%,73.53%,75%, respectively,which have an advantage over the predictive outcomes with ER or HER2.Conclusions:(1)A formula of PI derived from the 16 genes was ultimatelly set up.(2)The formula of PI might be used to predict the outcomes of the patients with EBC.(3)The formula of PI has an advantage over ER or HER2 in predicting prognosis of patiens with EBC. |